Marginated neutrophils in the lungs effectively compete for nanoparticles targeted to the endothelium, serving as a part of the reticuloendothelial system
Marco E Zamora,Eno-Obong Essien,Kartik Bhamidipati,Aditi Murthy,Jing Liu,Hyunjun Kim,Manthan N Patel,Jia Nong,Zhicheng Wang,Carolann Espy,Fatima Chaudhry,Laura T Ferguson,Sachchidananda Tiwari,Elizabeth Hood,Oscar A Marcos-Contreras,Serena Omo-Lamai,Tea Shuvaeva,Evguenia Arguiri,Jichuan Wu,Lubica Rauova,Mortimer Poncz,Maria C Basil,Edward Cantu,Joseph D Planer,Kara Spiller,Jarod Zepp,Vladimir Muzykantov,Jacob W Myerson,Jacob S Brenner
DOI: https://doi.org/10.1101/2024.06.07.597904
2024-06-10
Abstract:Nanomedicine has long pursued the goal of targeted delivery to specific organs and cell types but has not achieved this goal with the vast majority of targets. One rare example of success in this pursuit has been the 25+ years of studies targeting the lung endothelium using nanoparticles conjugated to antibodies against endothelial surface molecules. However, here we show that such 'endothelial-targeted nanocarriers' also effectively target the lung's numerous marginated neutrophils, which reside in the pulmonary capillaries and patrol for pathogens. We show that marginated neutrophils' uptake of many of these 'endothelial-targeted nanocarriers' is on par with endothelial uptake. This generalizes across diverse nanomaterials and targeting moieties and was even found with physicochemical lung tropism (i.e., without targeting moieties). Further, we observed this in ex vivo human lungs and in vivo healthy mice, with an increase in marginated neutrophil uptake of nanoparticles caused by local or distant inflammation. These findings have implications for nanomedicine development for lung diseases. These data also suggest that marginated neutrophils, especially in the lungs, should be considered a major part of the reticuloendothelial system (RES), with a special role in clearing nanoparticles that adhere to the lumenal surfaces of blood vessels.
Bioengineering